Literature DB >> 22051115

Chronic alloantibody mediated rejection.

R Neal Smith1, Robert B Colvin.   

Abstract

Alloantibodies clearly cause acute antibody mediated rejection, and all available evidence supports their pathogenic etiology in the development of chronic alloantibody mediated rejection (CAMR). But the slow evolution of this disease, the on-going immunosuppression, the variations in titer of alloantibodies, and variation in antigenic targets all complicate identifying which dynamic factors are most important clinically and pathologically. This review highlights the pathological factors related to the diagnosis of CAMR, the time course and natural history of this disease. What is known about CAMR pathogenesis is discussed including alloantibodies, the role of complement, gene activation, and Fc effector cell function. Therapy, which is problematic for this disease, is also discussed, including on-going and potential therapies and their limitations.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22051115      PMCID: PMC3728653          DOI: 10.1016/j.smim.2011.09.002

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  120 in total

Review 1.  Transplant glomerulopathy.

Authors:  F G Cosio; J M Gloor; S Sethi; M D Stegall
Journal:  Am J Transplant       Date:  2008-03       Impact factor: 8.086

2.  B cells in cluster or in a scattered pattern do not correlate with clinical outcome of renal allograft rejection.

Authors:  Cornelis Scheepstra; Fréderike J Bemelman; Chris van der Loos; Ajda T Rowshani; Karlijn A M I van Donselaar-Van der Pant; Mirza M Idu; Ineke J M ten Berge; Sandrine Florquin
Journal:  Transplantation       Date:  2008-09-27       Impact factor: 4.939

3.  CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy.

Authors:  Ping Zhou; Raymond L Comenzo; Adam B Olshen; Ezio Bonvini; Scott Koenig; Peter G Maslak; Martin Fleisher; James Hoffman; Suresh Jhanwar; James W Young; Stephen D Nimer; Adam M Boruchov
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

4.  Expression of B cell and immunoglobulin transcripts is a feature of inflammation in late allografts.

Authors:  G Einecke; J Reeve; M Mengel; B Sis; S Bunnag; T F Mueller; P F Halloran
Journal:  Am J Transplant       Date:  2008-07       Impact factor: 8.086

Review 5.  BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?

Authors:  Meera Ramanujam; Anne Davidson
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

6.  Characterization of intra-graft B cells during renal allograft rejection.

Authors:  Valeriya Zarkhin; Neeraja Kambham; Li Li; Shirley Kwok; Szu-Chuan Hsieh; Oscar Salvatierra; Minnie M Sarwal
Journal:  Kidney Int       Date:  2008-06-11       Impact factor: 10.612

7.  Decay-accelerating factor expression may provide immunoprotection against antibody-mediated cardiac allograft rejection.

Authors:  Gonzalo V González-Stawinski; Carmela D Tan; Nicholas G Smedira; Randall C Starling; E Rene Rodríguez
Journal:  J Heart Lung Transplant       Date:  2008-04       Impact factor: 10.247

Review 8.  Regulation of B-cell entry into the cell cycle.

Authors:  Sabrina Richards; Chie Watanabe; Lorna Santos; Andrew Craxton; Edward A Clark
Journal:  Immunol Rev       Date:  2008-08       Impact factor: 12.988

9.  B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.

Authors:  Olivier Thaunat; Natacha Patey; Chantal Gautreau; Sophie Lechaton; Véronique Fremeaux-Bacchi; Marie-Caroline Dieu-Nosjean; Elisabeth Cassuto-Viguier; Christophe Legendre; Michel Delahousse; Philippe Lang; Jean-Baptiste Michel; Antonino Nicoletti
Journal:  Transplantation       Date:  2008-06-15       Impact factor: 4.939

10.  Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys.

Authors:  R N Smith; T Kawai; S Boskovic; O Nadazdin; D H Sachs; A B Cosimi; R B Colvin
Journal:  Am J Transplant       Date:  2008-06-28       Impact factor: 8.086

View more
  17 in total

Review 1.  The impact of donor-specific anti-HLA antibodies on late kidney allograft failure.

Authors:  Alexandre Loupy; Gary S Hill; Stanley C Jordan
Journal:  Nat Rev Nephrol       Date:  2012-04-17       Impact factor: 28.314

Review 2.  B Cells, Antibodies, and More.

Authors:  William Hoffman; Fadi G Lakkis; Geetha Chalasani
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-23       Impact factor: 8.237

Review 3.  Lessons and limits of mouse models.

Authors:  Anita S Chong; Maria-Luisa Alegre; Michelle L Miller; Robert L Fairchild
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

4.  T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway.

Authors:  Jose-Ignacio Rodriguez-Barbosa; Carlos Fernandez-Renedo; Ana María Bravo Moral; Leo Bühler; Maria-Luisa Del Rio
Journal:  Cell Mol Immunol       Date:  2016-02-29       Impact factor: 11.530

Review 5.  ABO-compatible liver allograft antibody-mediated rejection: an update.

Authors:  Anthony J Demetris; Adriana Zeevi; Jacqueline G O'Leary
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

6.  Lupus-Prone Mice Resist Immune Regulation and Transplant Tolerance Induction.

Authors:  B T Stocks; A J Wilhelm; C S Wilson; A F Marshall; N E Putnam; A S Major; D J Moore
Journal:  Am J Transplant       Date:  2015-09-15       Impact factor: 8.086

7.  Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig.

Authors:  J Chen; H Yin; J Xu; Q Wang; K L Edelblum; R Sciammas; A S Chong
Journal:  Am J Transplant       Date:  2013-07-15       Impact factor: 8.086

8.  Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy.

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Transplant       Date:  2014-03-24

Review 9.  Effector and regulatory B cells in immune-mediated kidney disease.

Authors:  Claudia Mauri; Alan D Salama; Kristine Oleinika
Journal:  Nat Rev Nephrol       Date:  2019-01       Impact factor: 28.314

Review 10.  Large Animal Models of Vascularized Composite Allotransplantation: A Review of Immune Strategies to Improve Allograft Outcomes.

Authors:  Abraham J Matar; Rebecca L Crepeau; Gerhard S Mundinger; Curtis L Cetrulo; Radbeh Torabi
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.